Synphora was founded in 1998 by Johan Stjernschantz, Bahram Resul and Iréne Aspman. The founders of the company are previous employees of Pharmacia-Upjohn and held key positions in the Xalatan project of Pharmacia. Xalatan, with 1.3 billion US dollar sales in 2004, acquired by Pfizer, was the first prostaglandin analogue developed for glaucoma treatment. Johan Stjernschantz, Professor of Pharmacology and Drug Development, and Bahram Resul, Associate Professor of Medicinal Chemistry, are the inventors of latanoprost, the active principle of Xalatan.
In 1997 he left Pharmacia and continued his research at Uppsala University where he served as Professor of Pharmacology and Drug Development between 1999 and 2004. The company is now exclusively focused on the pharmacological treatment of diseases of the inner ear, specifically Menière’s disease and noise-induced tinnitus.